Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KNOCKOUT: High-dose Risankizumab for Plaque Psoriasis
NCT05283135Phase 2Completed
- Sponsor
- Oregon Medical Research Center
- Start
- Mar 2022
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of risankizumab in plaque psoriasis, sponsored by Oregon Medical Research Center. Started Mar 2022; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05283135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283135.